These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8204512)

  • 21. Importance of dose intensity in neuro-oncology clinical trials: summary report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium.
    Doolittle ND; Anderson CP; Bleyer WA; Cairncross JG; Cloughesy T; Eck SL; Guastadisegni P; Hall WA; Muldoon LL; Patel SJ; Peereboom D; Siegal T; Neuwelt EA
    Neuro Oncol; 2001 Jan; 3(1):46-54. PubMed ID: 11305417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Etoposide, mitoxantrone and prednisone: a salvage regimen with low toxicity for refractory or relapsed non-Hodgkin's lymphoma.
    Doorduijn JK; Spruit P; van Der Holt B; van't Veer M; Budel L; Löwenberg B; Sonneveld P
    Haematologica; 2000 Aug; 85(8):814-9. PubMed ID: 10942927
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early treatment intensification for aggressive non-Hodgkin's lymphoma.
    Swinnen LJ
    Curr Opin Oncol; 2006 Sep; 18(5):415-6. PubMed ID: 16894286
    [No Abstract]   [Full Text] [Related]  

  • 24. Aggressive non-Hodgkin's lymphoma: economics of high-dose therapy.
    Beard SM; Wall L; Gaffney L; Sampson F
    Pharmacoeconomics; 2004; 22(4):207-24. PubMed ID: 14974872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose chemotherapy followed by autologous and allogeneic hematopoietic stem cell transplantation in patients with follicular non-Hodgkin’s lymphoma in the rituximab era.
    Escobar IG; Sánchez de Ibarguen BC; de Juan VC; Alonso CM; García MM; Ruíz AC; Pulla MP
    Tumori; 2015; 101(1):2-7. PubMed ID: 25702654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The importance of dose: lymphomas as a model of chemosensitive malignancies.
    Bronchud MH
    Eur J Cancer; 1993; 29A Suppl 5():S17-22. PubMed ID: 8260261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment of aggressive non-Hodgkin's lymphomas].
    López A; Palacio C
    Med Clin (Barc); 1998 May; 110(16):614-8. PubMed ID: 9656199
    [No Abstract]   [Full Text] [Related]  

  • 28. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
    Kanteti R; Miller K; McCann J; Roitman D; Morelli J; Hurley C; Berkman E; Schenkein D
    Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of hematopoietic growth factors to support cytotoxic chemotherapy for patients with breast cancer.
    Demetri GD
    Hematol Oncol Clin North Am; 1994 Feb; 8(1):233-49. PubMed ID: 8150782
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
    Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP
    Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biotherapy in hematology: the next decade.
    Quesenberry PJ
    Rev Invest Clin; 1994 Apr; Suppl():8-15. PubMed ID: 7886315
    [No Abstract]   [Full Text] [Related]  

  • 32. Risk models for chemotherapy-induced neutropenia in non-Hodgkin's lymphoma.
    Zelenetz AD
    Oncology (Williston Park); 2003 Nov; 17(11 Suppl 11):21-6. PubMed ID: 14682115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effectiveness of dose-intensive polychemotherapy with autologous hemopoietic cell transplantation for high-grade non-Hodgkin lymphoma].
    Alekseeva IuA; Zaritskiĭ AIu; Medvedeva NV; Mikhaĭlova NB; Zubarovskaia LS; Afanas'ev BV
    Vopr Onkol; 2003; 49(1):66-70. PubMed ID: 12715373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytokine efficiency in the treatment of high-grade malignant non-Hodgkin's lymphomas: results of a randomized double-blind placebo-controlled study with intensified COP-BLAM +/- rhGM-CSF.
    Engelhard M; Gerhartz H; Brittinger G; Engert A; Fuchs R; Geiseler B; Gerhartz D; Haunauske AR; Hartlapp HJ; Huhn D
    Ann Oncol; 1994; 5 Suppl 2():123-5. PubMed ID: 7515644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of the low-grade non-Hodgkin's lymphomas.
    Portlock CS
    Semin Oncol; 1990 Feb; 17(1):51-9. PubMed ID: 2406918
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical trials referral resource. Current clinical trials in non-Hodgkin's lymphoma.
    Cheson BD; West PJ
    Oncology (Williston Park); 2002 Jun; 16(6):762-3, 766. PubMed ID: 12088298
    [No Abstract]   [Full Text] [Related]  

  • 37. Efficacy of intensive, high-dose anthracycline-based therapy in intermediate- and high-grade non-Hodgkin's lymphomas.
    Zuckerman KS
    Semin Oncol; 1994 Feb; 21(1 Suppl 1):59-64. PubMed ID: 8153658
    [No Abstract]   [Full Text] [Related]  

  • 38. High-dose therapy for aggressive non-Hodgkin's lymphoma.
    Pettengell R
    Br J Hosp Med; 1996 Nov 20-Dec 10; 56(10):521-4. PubMed ID: 8958405
    [No Abstract]   [Full Text] [Related]  

  • 39. Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.
    Haq R; Sawka CA; Franssen E; Berinstein NL
    Leuk Lymphoma; 1999 Nov; 35(5-6):527-36. PubMed ID: 10609790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
    Philip T; Guglielmi C; Hagenbeek A; Somers R; Van der Lelie H; Bron D; Sonneveld P; Gisselbrecht C; Cahn JY; Harousseau JL
    N Engl J Med; 1995 Dec; 333(23):1540-5. PubMed ID: 7477169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.